Pfizer (PFE) Other Non-Current Liabilities (2009 - 2026)
Pfizer (PFE) posted quarterly Other Non-Current Liabilities of $14.2 billion for Q1 2026, up 6.79% year-over-year from $13.3 billion in Q1 2025, and down 3.57% quarter-over-quarter from $14.7 billion in Q4 2025.
Pfizer (PFE) Other Non-Current Liabilities (2009 - 2026) Analysis & Trends
Pfizer (PFE) has reported Other Non-Current Liabilities for 18 consecutive years, with $14.2 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non-Current Liabilities rose 6.79% year-over-year to $14.2 billion; the TTM figure through Mar 2026 stood at $14.2 billion (up 6.79% YoY), while the FY2025 annual figure was $14.7 billion, up 140.92% from the prior year.
- Other Non-Current Liabilities retreated to $14.2 billion in Q1 2026 per PFE's latest filing, from $14.7 billion in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $16.5 billion in Q4 2023 and bottomed at $6.1 billion in Q4 2024.
- Historically, Other Non-Current Liabilities has averaged $13.1 billion across 5 years, with a median of $13.6 billion in 2025.
- Annual changes were most pronounced in 2024 — Other Non-Current Liabilities slumped 63.04% — and 2025, when it surged 140.92%.
- Pfizer's Other Non-Current Liabilities stood at $13.2 billion in 2022, then grew by 25.49% to $16.5 billion in 2023, then plunged by 63.04% to $6.1 billion in 2024, then soared by 140.92% to $14.7 billion in 2025, then retreated by 3.57% to $14.2 billion in 2026.
- Business Quant data shows PFE's Other Non-Current Liabilities at $14.2 billion in Q1 2026, $14.7 billion in Q4 2025, and $13.6 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.77 Bn | 632.01 Bn | 17.26 Bn |
| 2 | AbbVie | 469.90 Bn | 463.33 Bn | 12.70 Bn |
| 3 | Merck | 377.04 Bn | 369.90 Bn | 12.21 Bn |
| 4 | Novartis Ag | 303.08 Bn | 295.39 Bn | 11.24 Bn |
| 5 | Astrazeneca | 257.74 Bn | 252.84 Bn | 12.86 Bn |
| 6 | Amgen | 236.46 Bn | 222.47 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 181.81 Bn | 178.63 Bn | 6.22 Bn |
| 8 | Pfizer | 159.20 Bn | 147.50 Bn | 10.94 Bn |
| 9 | Gsk | 106.28 Bn | 102.11 Bn | 8.24 Bn |
| 10 | Sanofi | 55.01 Bn | 47.63 Bn | 10.79 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 28, 2026 | 14.78 Bn |
| Mar 29, 2026 | 14.20 Bn |
| Dec 31, 2025 | 14.73 Bn |
| Sep 28, 2025 | 13.61 Bn |
| Jun 29, 2025 | 13.93 Bn |
| Mar 30, 2025 | 13.30 Bn |
| Dec 31, 2024 | 6.11 Bn |
| Sep 29, 2024 | 15.57 Bn |
| Jun 30, 2024 | 16.10 Bn |
| Mar 31, 2024 | 15.12 Bn |
| Dec 31, 2023 | 16.54 Bn |
| Jul 2, 2023 | 8.05 Bn |
| Apr 2, 2023 | 13.01 Bn |
| Dec 31, 2022 | 13.18 Bn |
| Jul 3, 2022 | 10.99 Bn |
| Apr 3, 2022 | 11.57 Bn |
| Dec 31, 2021 | 9.74 Bn |
| Oct 3, 2021 | 9.20 Bn |
| Jul 4, 2021 | 8.23 Bn |
| Apr 4, 2021 | 6.68 Bn |